The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
N-(4-fluorophenethyl)-2-(4-hydroxy-2-oxopyridin-1(2H)-yl)-4-methylthiazole-5-carboxamide ID: ALA3104408
PubChem CID: 54742336
Max Phase: Preclinical
Molecular Formula: C18H16FN3O3S
Molecular Weight: 373.41
Molecule Type: Small molecule
This compound is available for customization.
Associated Items:
Names and Identifiers Canonical SMILES: Cc1nc(-n2ccc(O)cc2=O)sc1C(=O)NCCc1ccc(F)cc1
Standard InChI: InChI=1S/C18H16FN3O3S/c1-11-16(17(25)20-8-6-12-2-4-13(19)5-3-12)26-18(21-11)22-9-7-14(23)10-15(22)24/h2-5,7,9-10,23H,6,8H2,1H3,(H,20,25)
Standard InChI Key: HGWXLMRDZPZHIF-UHFFFAOYSA-N
Molfile:
RDKit 2D
26 28 0 0 0 0 0 0 0 0999 V2000
15.6808 -19.2127 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
14.9881 -18.7789 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
14.9689 -17.9611 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
14.1845 -17.7287 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
13.7221 -18.4039 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
14.2223 -19.0513 0.0000 S 0 0 0 0 0 0 0 0 0 0 0 0
13.9111 -16.9586 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
12.9052 -18.4273 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
12.4765 -17.7316 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
12.5171 -19.1465 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
11.6597 -17.7551 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
11.2309 -17.0594 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
10.4186 -17.0865 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
15.6461 -20.0295 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
16.3346 -20.4631 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
17.0588 -20.0839 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
17.0903 -19.2664 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
16.3975 -18.8281 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
16.4268 -18.0114 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
17.7497 -20.5204 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
9.9940 -16.3966 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
9.1824 -16.4234 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
8.7989 -17.1409 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
9.2330 -17.8331 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
10.0431 -17.8029 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
7.9822 -17.1693 0.0000 F 0 0 0 0 0 0 0 0 0 0 0 0
1 2 1 0
3 4 1 0
2 3 2 0
4 5 2 0
5 6 1 0
6 2 1 0
4 7 1 0
5 8 1 0
8 9 1 0
8 10 2 0
9 11 1 0
11 12 1 0
13 12 1 0
1 14 1 0
1 18 1 0
14 15 2 0
15 16 1 0
16 17 2 0
17 18 1 0
18 19 2 0
16 20 1 0
13 21 2 0
21 22 1 0
22 23 2 0
23 24 1 0
24 25 2 0
25 13 1 0
23 26 1 0
M END Associated Targets(Human) Associated Targets(non-human) Molecule Features Natural Product: NoOral: NoChemical Probe: NoParenteral: NoMolecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: NoChirality: NoAvailability: NoProdrug: No
Drug Indications MESH ID MESH Heading EFO IDs EFO Terms Max Phase for Indication References
Mechanisms of Action Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References
Calculated Properties Molecular Weight: 373.41Molecular Weight (Monoisotopic): 373.0896AlogP: 2.42#Rotatable Bonds: 5Polar Surface Area: 84.22Molecular Species: NEUTRALHBA: 6HBD: 2#RO5 Violations: ┄HBA (Lipinski): 6HBD (Lipinski): 2#RO5 Violations (Lipinski): ┄CX Acidic pKa: 7.61CX Basic pKa: ┄CX LogP: 2.34CX LogD: 2.13Aromatic Rings: 3Heavy Atoms: 26QED Weighted: 0.72Np Likeness Score: -1.50
References 1. Sun S, Zhang Z, Raina V, Pokrovskaia N, Hou D, Namdari R, Khakh K, Ratkay LG, McLaren DG, Mork M, Fu J, Ferreira S, Hubbard B, Winther MD, Dales N.. (2014) Discovery of thiazolylpyridinone SCD1 inhibitors with preferential liver distribution and reduced mechanism-based adverse effects., 24 (2): [PMID:24370012 ] [10.1016/j.bmcl.2013.12.035 ]